Assessing Bio-Rad Laboratories (BIO) Valuation After Recent Share Price Rebound And ddPCR Growth Prospects

Recent performance snapshot

Bio-Rad Laboratories (BIO) has drawn investor attention after a mixed run. The stock is up 13.9% over the past day and 15.6% over the past week, but down 5.8% over the past month.

See our latest analysis for Bio-Rad Laboratories.

At a share price of US$281.82, Bio-Rad’s recent bounce contrasts with a year to date share price return that is down 7.7%, while the 1 year total shareholder return of 13.3% and weaker 3 and 5 year total shareholder returns suggest recent momentum is rebuilding after a tougher multi year stretch.

If you are weighing up opportunities in life sciences and diagnostics, it can also be useful to see how other healthcare focused AI stocks are trading right now through the 31 healthcare AI stocks

With modest annual growth in revenue and net income, and a share price only slightly below one analyst price target and an intrinsic value estimate, the key question is whether Bio-Rad is quietly undervalued or if the market already reflects future growth.

Most Popular Narrative: 3.8% Undervalued

At a last close of $281.82 versus a narrative fair value of $293.00, Bio-Rad is framed as modestly undervalued, with the story hinging on gradual earnings and margin progress rather than rapid expansion.

Recent launch and expansion of the QX Continuum and QX700 Series ddPCR platforms, alongside the acquisition of Stilla Technologies, positions Bio-Rad to accelerate its share capture as demand grows for advanced molecular diagnostics and precision medicine tools; this is expected to drive ddPCR revenue growth and improve margins through higher consumable pull-through and broader assay adoption.

Read the complete narrative.

Want to see the math behind that fair value? The narrative leans on steady revenue growth, improving profit margins and a richer earnings multiple. Curious how those pieces fit together into $293.00?

Result: Fair Value of $293 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are real pressure points to watch, including softer instrument demand and gross margin pressure from higher material costs and underused manufacturing capacity.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Next Steps

There is clearly a split story here, with both risk and reward signals in play. It makes sense to pressure test the data yourself rather than relying on headlines. To see how those tension points balance out for Bio-Rad right now, take a closer look at the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your style even better, so put the broader market to work for you.

• Spot potential turnaround opportunities early by scanning 29 elite penny stocks with strong financials that already show stronger financial footing than many expect.
• Zero in on quality at a sensible price by reviewing 52 high quality undervalued stocks that pair solid fundamentals with attractive valuations.
• Prioritize resilience and peace of mind by filtering for 65 resilient stocks with low risk scores that aim to keep volatility in check while you focus on the long term.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com